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Abstract
“LONG-TERM MORTALITY FOR OLDER DIABETICS HOSPITALIZED WITH ACUTE
MYOCARDIAL INFARCTION”
Marwah Abdalla,1 Barbara Gulanski,1 Yun Wang,1 Edward Havranek,2 Frederick Masoudi,2 Harlan
Krumholz,1 JoAnne Micale Foody.1 1Yale University School of Medicine-New Haven, CT & 2University of
Colorado Health Sciences-Denver, CO 3
Diabetics have higher mortality after myocardial infarction (MI), yet little is known regarding the
impact of quality of care on long-term survival in older post-MI diabetics. Using data from the
Cooperative Cardiovascular Project (CCP), a national cohort of 234,769 Medicare patients aged 65 or older
hospitalized with confirmed AMI between 1994-1995, we assessed differences in 10-year mortality
outcomes between diabetics and non-diabetics using Cox proportional regression. To account for quality of
care, a composite measure among ideal candidates was constructed and entered into the final model
adjusting for use of aspirin & beta-blocker on admission/discharge, angiotensin-converting enzyme
inhibitors at discharge, reperfusion within 6 hours of admission, and smoking counseling at discharge. We
also assessed the relationship between insulin use, sulfonylureas/biguanides, and statin therapy and longterm mortality within the diabetic cohort.
The final study sample included 203,658 cases: 32% were diabetics. Compared to non-diabetics,
diabetics were younger (75 vs. 76, p<0.001), female (53% vs. 47%, p<0.001), had more comorbidities, and
unlikely to receive evidence-based care (59% vs. 64%, p<0.001). The unadjusted HR for mortality among
diabetics vs. non-diabetics was 1.38 (95% CI: 1.37-1.40). After adjusting for demographics, past medical
history, procedures during hospitalization, medications on admission/discharge, and quality of care, the HR
was 1.29 (95% CI: 1.27-1.31). Among diabetics, those on insulin or oral hypoglycemic therapy during the
initial hospitalization for AMI had the highest risk of mortality during the last 7 years, after adjustment for
demographics, clinical characteristics, and quality of care (HR insulin=1.30, 95% CI: 1.25-1.35; HR oral
hypoglycemics=1.11, 95% CI: 1.08-1.15) whereas those on statin therapy were not at increased risk (HR
statin=0.95, 95% CI: 0.90-1.02).
As compared to non-diabetics, older diabetics had a 29% increase in mortality even after adjusting
for demographics, clinical variables during hospitalization, and quality of care (HR=1.29, 95% CI: 1.271.31). Additionally, within the diabetic cohort, the risk of long-term mortality was highest among those on
insulin or oral hypoglycemic therapy during initial hospitalization for AMI. Our study demonstrates that
neither patient characteristics nor quality of care fully account for the poor outcomes among diabetics
suggesting that metabolic risk factors associated with diabetes ultimately require therapies beyond those
currently recommended for post-MI patients.
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I. Introduction
Worldwide, cardiovascular disease (CVD) is the leading cause of death (3). The
World Health Organization (WHO) estimates that 17 million people die of cardiovascular
disease annually, of which 7.2 million deaths are attributable to coronary heart disease
(CHD) alone (1). In the U.S., CHD is the leading cause of death (Table 1; Figure 2-3).
In 2002, 1 out of every 5 deaths was attributable to CHD (9). Of those who die of CHD,
83% are over the age of 65 (11). According to the American Heart Association (AHA),
in the U.S., acute myocardial infarction (AMI), a subset of CHD caused over 175,000
deaths and led to over $27 billion in healthcare spending in 2002 (9). Additionally, those
who have suffered an AMI are more likely to experience sudden cardiac death at a rate 4
to 6 times higher than the general population (9).

Table 1: Estimated Prevalence and Mortality from Cardiovascular and Coronary Heart
Disease in the U.S. By Race and Gender-Year 2003. Source: “The Atlas of Heart
Disease and Stroke” American Heart Association-Modified Table 3 (1)
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Figure 1-2: Taken from: “The Atlas of Heart Disease and Stroke” American Heart
Association, pg 9 (1).
While traditional risk factors such as smoking, abnormal lipid levels,
hypertension, abdominal obesity, and lack of physical activity have long been implicated
in the pathophysiology leading to the development of AMI, diabetes is also a strong risk
factor for CHD and has even been described by the AHA as a “cardiovascular disease”
(12). Worldwide, it is estimated that there are 177 million diabetics and diabetes is now
the fifth leading cause of death (13). Currently in the U.S., there are 20.8 million
diabetics, of whom 5.2 million also have CHD (Figure 3) (5). While microcomplications
such as nephropathy, neuropathy, and retinopathy have long been recognized as causes of
increased morbidity and mortality for diabetics, CHD, and in particular AMI, has now
become the leading cause of death for diabetics, affecting approximately 55% of patients
(14, 15). In fact, of patients hospitalized with AMI, it is estimated that 30% have
diabetes (16). Not only are diabetics at a greater risk of developing CHD (17) but once
they have cardiovascular complications (i.e. myocardial infarction, congestive heart
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failure (CHF), arrhythmias, or strokes) they have an increased short-term morbidity and
mortality.

Figure 3: Number of Diabetics in Millions (age 35 and older) with Self-Reported
Cardiovascular Disease (1997-2003) Source: Centers for Disease Control and Prevention
(CDC) (5)
Unfortunately, the prevalence of diabetes is increasing steadily especially among
the elderly (Figure 4; Appendix 1-2) (8). Additionally, as depicted in Figure 5, among
diabetics, the elderly also have the highest prevalence of cardiovascular disease. As the
population ages the interaction of diabetes and cardiovascular disease will potentially be
one of the leading public health problems facing the world and efforts to understand and
combat these diseases will be essential.
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Figure 4: Prevalence of Diabetes Worldwide by Age and Sex in the Year 2000
Source: Wild et al., “Global Prevalence of Diabetes: Estimates for the Year 2000
and Projections for 2030” (Figure 1) (8)

Figure 5: Prevalence of any Cardiovascular Disease Among Diabetics by Age (age
35 and older) (1997-2003: Self-Reported) Source: Centers for Disease Control and
Prevention (CDC), National Center for Health Statistics, Division of Health
Interview Statistics, data from the National Health Interview Survey (5).
Although this past decade has been instrumental in characterizing some of the
reasons behind the increased morbidity and short-term mortality of diabetics post-MI and
while more aggressive secondary prevention efforts have been put in place, diabetics still
fare worse during hospitalization for MI as compared with non-diabetics. While much is
known about short-term mortality in diabetics post-MI, less is known about long-term
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mortality in this group. Furthermore, little is known about long-term mortality in older
patients. Thus, this thesis will characterize long-term outcomes for older diabetics
hospitalized with AMI. It is anticipated that results from this study will advance current
knowledge about the interaction between diabetes and cardiovascular disease.

Morbidity and Mortality: Increased Risk after an Acute MI
One area which has been researched extensively has been the impact of diabetes
on the short-term morbidity and mortality associated with AMI (12, 18-23). It has been
shown in several studies that after suffering an AMI, diabetics have worse outcomes
compared to their non-diabetic counterparts (12, 18-23) although controversy exists
whether these worse outcomes are related to the increased comorbid conditions diabetics
have. For example, Chyun et al. analyzed the medical records of Connecticut Medicare
beneficiaries aged 65 or older who were 30-day survivors of AMI to determine their risk
of recurrent MI, CHF, and mortality rates one year post hospital discharge. Results
showed that at baseline, compared to non-diabetic patients, diabetics were more likely to
have comorbid conditions such as CHF, stroke, chronic renal insufficiency, MI,
peripheral vascular disease and hypertension (p<0.001). Analysis of 1-year mortality
rates showed that the unadjusted relative risk of death was highest among diabetics,
especially non-insulin dependent diabetics (RR=1.55, 95% CI: 1.18-2.03). However after
adjusting for comorbid conditions, clinical findings, and myocardial characteristics at
time of admission, this no longer remained statistically significant (RR=1.08, 95% CI:
0.82-1.43). In terms of the risk for developing complications, the study showed that the
relative risk of readmission for recurrent MI was highest for diabetics. Furthermore,
insulin-dependent diabetics were the group most likely to be readmitted for CHF

6
(RR=2.00, 95% CI: 1.40-2.86) (22). On the other hand, in a retrospective cohort study of
117,599 Medicare patients hospitalized with AMI, Berger et al. showed that diabetic
patients had higher 30-day and 1-year mortality rates when compared to non-diabetics
after adjusting for differences in comorbidities. Furthermore, among the three different
subgroups of diabetics (diet-controlled, on oral agents, on insulin), insulin-treated
diabetics had the highest mortality at 30 days and one year even after adjustment for
therapeutic interventions, clinical, demographic, and hospital characteristics (OR=1.14,
95% CI: 1.08-1.20 for 30-day mortality; OR=1.48, 95% CI: 1.41-1.55 for 1-year
mortality) (24).
Congestive heart failure, along with increased rates of reinfarction and recurrent
ischemia, has been noted to be one of the primary causes of the excess in-hospital
mortality of diabetic patients post-MI (18, 19). Jaffe et al. found that although diabetic
patients had an increased incidence of CHF post-MI, they tended to have smaller infarct
sizes when compared to non-diabetics, suggesting that there are other additional factors
yet unidentified which may contribute to the excess mortality risk (12, 19, 25-27).
Although somewhat controversial, some studies have demonstrated that diabetic patients
have more severe coronary atherosclerosis than non-diabetic patients (18, 28-30),
suggesting that there are metabolic derangements, such as clotting abnormalities or
microvascular disease that place diabetic patients at higher risk of CHD (31). In yet
another study, although somewhat controversial, Haffner et al. demonstrated that
diabetics without prior MI have similar mortality rates compared to non-diabetics with
prior MI even after adjusting for LDL/HDL cholesterol levels, triglycerides, smoking,

7
and hypertension (HR=1.2, 95% CI: 0.6-2.4) leading the authors to conclude that diabetic
patients should be treated as aggressively as non-diabetic patients with prior MI (32).
Whether the increased mortality risk seen in diabetics can be explained by
inherent biological differences between diabetics and non-diabetics or whether treatment
differences in terms of the quality of care diabetics receive post-MI account for the
increased mortality has been extensively debated and is explored in our own study via
analysis of the Cooperative Cardiovascular Project (CCP), a national database established
to examine quality of care for Medicare patients hospitalized with AMI between 19941995. First, however, in order to fully understand the background of this debate and the
results from our own study, a review of the biology of AMI in diabetics and the
established treatment guidelines for the care of diabetic patients post-MI during 19941995 (the time period when initial data for the CCP cohort was collected) is warranted.

Understanding the Pathophysiology of Atherosclerosis and AMI in Diabetics
Traditional risk factors for AMI such as hyperlipidemia, obesity, and hypertension
affect diabetics and non-diabetics in a similar fashion. In a follow-up study of the United
Kingdom Prospective Diabetes Study (UKPDS), Turner et al. demonstrated that among
type 2 diabetics increased low density lipoprotein cholesterol (LDL), decreased high
density lipoprotein cholesterol (HDL), hyperglycemia, hypertension, and smoking were
all risk factors for coronary artery disease including fatal and non-fatal myocardial
infarction (33). Interestingly, the study showed that lipids (increased LDL and decreased
HDL) and hypertension were more predictive as risk factors for non-fatal or fatal
myocardial infarction rather than hyperglycemia (33). From the results of their study, the
authors concluded that type 2 diabetics have similar risk factors for coronary artery
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disease as non-diabetics. However, even after controlling for these traditional risk
factors, there are additional risk factors which may partially explain the increased risk of
cardiovascular disease which diabetes confers on patients. Insulin resistance leading to
hyperglycemia, hyperinsulinemia, atherogenic dyslipidemia, and a prothrombotic state
are independent risk factors especially in type 2 diabetes that increase the risk of
cardiovascular mortality (12, 34). For example, atherogenic dyslipidemia, characterized
by three lipoprotein abnormalities—elevated very-low density lipoprotein (VLDL), small
dense LDL particles, and low HDL cholesterol, appears frequently in those with insulin
resistance. Besides elevated LDL cholesterol, these lipid abnormalities may
independently lead to atherosclerosis (12). Additionally, Zareba et al. demonstrated in a
study examining 1,045 non-diabetic and diabetic patients post-MI that diabetic patients,
especially insulin-dependent diabetics, had higher levels of von Willebrand factor as
compared to non-diabetics after adjusting for confounders (35). The authors concluded
that endothelial damage is most likely one of the primary mechanisms leading to the
increased mortality seen in diabetics post-MI. In fact, it has been shown that diabetics
have impaired endothelium-dependent relaxation (18, 36).
In terms of hyperglycemia, results from another UKPDS follow-up study in 2000,
revealed that for every 1% decrease in HbA1c levels, the risk for myocardial infarction in
diabetics could be reduced by 14% (37). Stevens et al. also used data from the UKPDS
to examine differences in risk factors for cardiovascular mortality due to myocardial
infarction and stroke (38). They found that those with fatal MIs had higher HbA1c
levels, measured within 2 years of diabetes diagnosis, as compared to those with nonfatal
MIs suggesting that long-term hyperglycemia impacts mortality rates within a diabetic
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cohort. Hyperglycemia, via the presence of advanced glycosylation end products, is
theorized to be one of the primary causes underlying this endothelial dysfunction and
may lead to an acceleration in atherogenesis (18, 39).
Additionally, in the setting of an acute MI, there are additional abnormalities that
place diabetics at increased risk for mortality. Central to the pathophysiology of AMI is
platelet aggregation and thrombosis (Figure 6). It is estimated that 90% of AMIs are
caused by an acute thrombus overlying an atherosclerotic coronary artery plaque (40).
The thrombus leads to further narrowing and complete occlusion of the coronary artery
leading to ischemia of the heart muscle (40). When a plaque ruptures, platelets are
activated via exposure to the underlying subendothelial collagen triggering the
coagulation pathway and thrombus formation (40). Activated platelets also release potent
vasoconstrictors such as thromboxane, which contributes to further narrowing of the
vessels (40). Because of the metabolic derangements found in diabetes, research has
focused on characterizing the pathophysiology of platelet function in diabetics presenting
with AMI. In general, diabetics have increased platelet aggregability and an increased
procoagulant state as measured by fibrinogen levels and plasminogen activator inhibitor1 (12, 41, 42). Studies have shown that platelets from diabetic patients produce increased
prostaglandins and thromboxane A2 (TXA2) relative to platelets from non-diabetic
patients (18, 43). The increased prostaglandins and TXA2 expose fibrinogen binding
sites on platelets, leading to the observed increase in platelet aggregation in diabetic
patients (44). Activated platelets also appear to be increased in diabetic patients even in
the absence of detectable vascular lesions (18). Because diabetics are prone to a more
hypercoagulable state, this suggests that they may more easily form thrombi causing
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them to experience more severe AMIs and thus have worse outcomes as compared to
their non-diabetic counterparts.

Myocardial Ischemia
Figure 6: Pathophysiology of Acute Myocardial Infarction-the Role of Platelets and
Thrombus Formation Leading to Myocardial Ischemia. IL-1:interleukin-1; TNF:
tumor necrosis factor-alpha. Source: www.images.med. Original figure taken
from: Murad M, Henry T: Unstable Angina. Current Treatment Options in
Cardiovascular Medicine. 2(1):37-54.
Exploring Differences in Quality of Care: Diabetics and the Elderly
Besides understanding how biological factors may confer an increased risk of
morbidity and mortality in diabetic patients with CHD, other research has centered on
identifying whether differences exist between diabetics and non-diabetics in terms of the
quality of care they receive. It has been noted that the clinical presentation of diabetics
with AMI may differ from that of a non-diabetic, with diabetics having “atypical
symptoms” due to autonomic neuropathy leading ultimately to a decreased recognition of
AMI (12). Because of impaired angina recognition by both patient and caregiver,
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important intervention therapies may be delayed and morbidity and mortality rates are
increased (16).
However, more concerning have been the studies that demonstrate when diabetics
suffer AMIs, they are unlikely to receive the same therapeutic interventions as their nondiabetic counterparts (21, 23, 24, 45-48). In a retrospective study of 1,982 Australian
patients, Lim et al. examined treatment differences between diabetics and non-diabetics
presenting with AMI between 1988-1994. Diabetics were less likely to be prescribed the
following therapies on admission: aspirin (76% vs. 85%, p<0.005), beta-blockers (41%
vs. 53%, p<0.001), or streptokinase (25% vs. 43%, p<0.001) (23). Similarly, Vaccarino
et al. also demonstrated in a larger study examining 160,773 patients aged 30 to 69
hospitalized with AMI between 1994-1998 that diabetics were less likely to receive
thrombolytic therapy (18.8/22.7% diabetic women/men vs. 27.6/32.5% non-diabetic
women/men), aspirin (74.7/80.5% diabetic women/men vs. 81.2/86.6% non-diabetic
women/men , oral beta-blockers (33.0/37.8% diabetic women/men vs. 37.9/42.3% nondiabetic women/men), or alternative reperfusion (9.7/11.7% diabetic women/men vs.
14.0/17.6% non-diabetic women/men) (47). Norhammar et al. in a retrospective analysis
of a Swedish registry also investigated treatment differences between diabetics and nondiabetics hospitalized with AMI between 1995-1998. During hospitalization, diabetics
were less likely to be treated with heparins (37% vs. 43%, p<0.001), intravenous betablockers (29% vs. 33%, p<0.001), thrombolysis (31% vs. 41%, p<0.001) and acute
revascularization (4% vs. 5%, p<0.003). Even after adjustment for comorbidities,
diabetics were still significantly less likely to be treated with reperfusion therapy
(OR=0.83, 95% CI: 0.77-0.89), heparins (OR=0.88, 95% CI: 0.82-0.94), statins
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(OR=0.88, 95% CI: 0.80-0.97), or undergo revascularization within 14 days of hospital
discharge (OR=0.86, 95% CI: 0.75-0.98) (21).
Using the same database as we did in our present study, Berger et al. analyzed
data from the CCP cohort (between January 1994-February 1996) and established that
diabetics were statistically less likely to receive aspirin on arrival, beta-blockers on
discharge, receive thrombolytics, undergo cardiac catherization, or coronary angioplasty.
Across subgroups of diabetics, patients on insulin therapy consistently received the least
appropriate care (24). A major limitation, however, of all the above studies is that
contraindications to medical therapy were not accounted for in these analyses. Given the
fact that diabetics are known to have more comorbidities, the finding of decreased use of
evidence-based therapies may in fact be due to more contraindications to therapy
secondary to the increased comorbidities diabetics face.
Both Chowdhury et al. and Krumholz et al. addressed this issue in their respective
studies. Like the other authors discussed above, Chowdhury et al. also examined rates of
prescription use among a small British cohort of 374 patients between January 1995December 1995 hospitalized with their first MI. Patients were prospectively evaluated
during admission and at one year. At follow-up, diabetic patients were statistically more
likely to have evidence of left ventricular failure (47.7% vs. 28.0%, p<0.01). However,
the proportion of diabetic patients with left ventricular failure that were prescribed
angiotensin-converting enzyme inhibitors (ACE-Is) was less (61% vs. 73.6%, p<0.01).
The same pattern was observed for lipid lowering therapy. Although total cholesterol
values (>5.5 mmol/L) were significantly higher among diabetic patients at time of 1 year
follow-up, they were less likely to be on lipid lowering therapy (27.9% vs. 37.5%,
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p<0.05). Although it did not reach statistical significance, the authors also found that the
proportion of diabetic patients on beta-blockers and aspirin was lower than for nondiabetics. When closely examined, diabetics had less contraindications to therapy as
compared to non-diabetics. The authors concluded that the lower usage of these therapies
was not based on contraindications but rather appeared to have little scientific-based
justification or explanation (48). Krumholz et al. also adjusted for contraindications to
therapy by limiting their cohort to ideal candidates for therapy. From analysis of CCP
data from 4 states, Alabama, Connecticut, Iowa, and Wisconsin, non-diabetics were more
likely to receive aspirin during hospitalization, aspirin and beta-blocker therapy at
discharge, and to undergo cardiac procedures. Using results from a multiple logistic
regression model, the authors reported that a history of diabetes was associated with
decreased use of aspirin (OR=0.81, 95% CI: 0.70-0.94) and that use of aspirin at
discharge was associated with decreased mortality rates 6 months post discharge
(OR=0.77, 95% CI: 0.61-0.98) (46).
Like diabetics, evidence exists that elderly patients are also less likely to receive
appropriate evidence-based care. Udvarhelyi et al. retrospectively examined differences
in processes and outcomes of care post-MI among a Medicare population (n=218,247
patients). The authors found that use of procedures such as angiography, coronary artery
bypass graft (CABG), and percutaneous transluminal coronary angioplasty (PTCA)
decreased with every 5 year increase in age, after adjustment for comorbidities,
suggesting that the most elderly patients are the least likely to undergo procedures as
compared to younger patients within the same Medicare population. Other authors have
also reported similar findings that suggest elderly patients are less likely to receive
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evidence-based care (10, 46, 49-55). Using data from the Worcester Heart Attack Study,
a prospective longitudinal study of 9,336 Worcester, Massachusetts residents hospitalized
with confirmed AMI between 1975-1997, Jackson et al. examined trends in aspirin
utilization and long-term outcomes. The authors demonstrated that over three time
periods (1975-1978, 1986-1988, and 1995-1997) diabetics and the elderly were less
likely to receive aspirin therapy. They also showed that over a 10-year follow-up period,
patients treated with aspirin during initial hospitalization for AMI had increased survival
after controlling for study year, patient age, sex, comorbidities, AMI characteristics, and
development of heart failure or cardiogenic shock during initial hospitalization
(HR=0.85, 95% CI: 0.78-0.92) (56). Given the results from studies like this one, it may
be appropriate to conclude that elderly diabetic patients may be the group least likely to
receive appropriate care due to the “double bias” against the elderly and diabetics in
general.
In an attempt to understand why certain populations such as the elderly and
diabetics do not receive appropriate evidence-based care, physician adherence to practice
guidelines has been extensively studied and various attempts to improve quality of care
have been initiated. One such attempt was the development of the CCP cohort. In 1992,
as part of the Health Care Quality Improvement Initiative, the Health Care Financing
Administration (HCFA, renamed in 2001 as the Centers for Medicare & Medicaid
Services [CMS]) created the CCP. The CCP was designed with the following four
objectives:
1) to develop quality indicators describing use of interventions in an ideal group
of patients with AMI,
2) to measure the quality of care by relying on these indicators for AMI patients
in Alabama, Connecticut, Iowa, and Wisconsin,
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3) to use these measurements to direct hospitals to develop quality improvement
mechanisms and,
4) to help the HCFA use the CCP as a prototype in the development of similar
quality improvement efforts for other conditions besides AMI (53).
Because of its success, the CCP was subsequently nationally expanded and is an ongoing
initiative. The CCP is a large well-known cohort that has been validated. Numerous
studies have been published over the past decade using data from the CCP that not only
have described treatment practices for patients with AMI but also have described changes
over time with regards to the quality of care patients hospitalized with AMI have received
(10, 22, 24, 51, 52, 55, 57, 58). Likewise, our study will also use data from the CCP to
examine quality of care. However, this will be the first time that data on long-term
mortality for diabetics will be presented controlling for differences in quality of care.
Because our study examines 10-year mortality, it is important to recognize and
understand the scientific environment at the time of our study and the potential paradigm
shifts in medical practice during this time period especially when interpreting results and
formulating conclusions. Thus, a brief history of some of the major controversies during
this time period is presented below.

Practice Guidelines: Management of AMI and Diabetes
As mentioned above, the CCP was developed in 1992 with four objectives. The
first objective was to develop quality indicators describing use of interventions in an ideal
group of patients with AMI. In order to achieve this objective, 11 quality of care
indicators were developed, based primarily on the 1990 American College of Cardiology
(ACC)/American Heart Association (AHA) treatment guidelines for the secondary
prevention of AMI. Some of the established guidelines that became the basis for these
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quality of care indicators were as follows: use of beta-blockers at admission/discharge,
use of aspirin at admission/discharge, use of ACE-Is in patients with low left ventricular
ejection fraction (LVEF <40%), avoidance of calcium channel blockers in patients with
low left ventricular ejection fraction (LVEF <40%), smoking cessation counseling, use of
percutaneous transluminal coronary angioplasty (PTCA) within six hours of onset of
chest pain who meet criteria for thrombolysis, use of thrombolytics on admission,
administration of heparin, and use of intravenous nitroglycerin for persistent chest pain
(53, 59).
Although it was recognized at this time that diabetics had increased mortality
post-MI, no separate guidelines for the secondary prevention of AMI existed for diabetic
patients during this time period. Thus, specific guidelines for diabetics were only
developed after 1995, after our study was initiated (12). Although the 1990 guidelines
did not specifically address diabetics, there were prevailing debates within the scientific
community about the applicability and the appropriateness of these therapies for diabetic
patients that merit discussion and may provide a framework for understanding why
diabetics may have been less likely to receive certain medications.
The 1990 ACC/AHA guidelines advised caution with regards to beta-blocker use
as secondary prevention in diabetics post-MI. The guidelines stated that one of the
relative contraindications to beta-blockade was “difficult to control insulin-dependent
diabetes” but did not further specify how this was defined (59). The argument against
beta-blocker use in diabetics was the theoretical belief that beta-blockers masked the
symptoms of hypoglycemia especially by blunting reflex tachycardia. However, studies
showed that there was no significant increase in the incidence of clinically important
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hypoglycemic events (60). Likewise, controversy also existed with regards to aspirin
therapy. In particular, aspirin was thought to increase the risk of ocular hemorrhages
among patients with diabetic retinopathy. Although the results from the Early Treatment
Diabetic Retinopathy Study (ETDRS) published in 1992 demonstrated that aspirin did
not increase the risk of ocular hemorrhage and that there was a small reduction in
cardiovascular events in diabetics (61), the American Diabetes Association (ADA) did
not officially recommend aspirin for all diabetics until 1997 (62).
Additionally, one of the major controversies at this time was regarding glucose
control and macrovascular complications. In 1993, one year prior to the start of our
study, the Diabetes Control and Complications Trial (DCCT) showed that intensive
control in type 1 diabetics helped decrease microvascular complications and showed a
non-statistically significant trend towards a reduction in macrovascular complications
(63, 64). Whether similar intensive glycemic control impacted outcomes for type 2
diabetics was unknown at the start of our study, however there were several ongoing
studies addressing this issue at that time. Two of the most important studies were the
Diabetes Mellitus Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI)
Study and the United Kingdom Prospective Diabetes Study (UKPDS)—both of which
later impacted practice guidelines.
The findings from the DIGAMI study, a randomized controlled trial, were
published in 1995 and demonstrated that diabetic patients randomized to an intensive
insulin regimen post-MI had decreased in-hospital and 1-year mortality (65). Findings
from the 3-year follow-up study published in 1997 also demonstrated that among those
that had been randomized to the intensive insulin regimen, an 11% reduction in mortality
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3 years post treatment was achieved (63, 66). In 1998, results from a randomized
controlled trial (RCT) embedded within the UKPDS 1 were published. This portion of the
UKPDS was designed to determine whether intensive therapy would reduce diabetic
microvascular and macrovascular complications. Although it did show an improvement
in microvascular outcomes, it only showed a borderline decrease in macrovascular
disease (67, 68). Reception of these findings by the scientific and medical community
were initially mixed but both studies became landmark articles that impacted practice
guidelines especially with regards to the use of insulin and oral hypoglycemics to achieve
better glycemic control. Because our study spans the time period when major changes in
quality of care and practice guidelines occurred, we will examine long-term mortality
outcomes at two time periods: pre- and post-1997/1998. We chose the years 1997/1998
because as discussed above, these were the years that aspirin therapy for diabetics was
endorsed by the ADA and the results of the DIGAMI and UKPDS studies were
published.
II. Statement of Purpose, Specific Aims, and Hypotheses
The purpose of this study was to examine overall outcomes for older diabetic
patients presenting with AMI and to examine the factors associated for the increased
mortality risk conferred on diabetics hospitalized with AMI by utilizing a national
database, the Cooperative Cardiovascular Project (CCP). Our aims were:
1) To measure and compare 10-year mortality rates for diabetic and non-diabetic
patients hospitalized with AMI.
2) To measure compliance rates with established guidelines in place during 19941995 regarding cardiac medications as a secondary prevention strategy among
diabetic and non-diabetic patients hospitalized with AMI.
1

The UKPDS was a 20 year prospective trial that recruited 5,102 patients with type 2 diabetes from 23
clinical centers in England, Scotland, and Northern Ireland.
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3) To investigate the role of statin and diabetic therapies (insulin/oral
hypoglycemics) in decreasing 3 and 10-year mortality rates for diabetics
hospitalized with AMI.
We hypothesize that:
1) 10-year mortality rates for diabetics will be higher as compared to non-diabetic
patients before and after adjustment for quality of care indicators.
2) Diabetic patients will be less likely to receive appropriate cardiac medications for
secondary prevention.
3) Both statin and diabetic therapies (insulin/oral hypoglycemics) will be associated
with decreased long-term mortality rates for diabetics.
III. Methods
Database Source/Selection:
We utilized the Cooperative Cardiovascular Project (CCP), a national database of
Medicare patients, (n=234,769) aged 65 or older admitted to non-governmental acute
care hospitals in the United States and Puerto Rico. As mentioned previously, the CCP
was designed with four objectives: 1) to develop quality indicators describing use of
interventions in an ideal group of patients with AMI; 2) to measure the quality of care by
relying on these indicators for AMI patients in Alabama, Connecticut, Iowa, and
Wisconsin; 3) to use these measurements to direct hospitals to develop quality
improvement mechanisms; and 4) to help the HCFA use the CCP as a prototype in the
development of similar quality improvement efforts for other conditions besides AMI
(53).

Sample Population & Data Collection
All bills submitted by acute care hospitals (UB-92 claims form data) and
contained in the Medicare National Claims History File, composed of Part A Medicare
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claims, were used to identify discharges (55). The Medicare National Claims History
File includes patients treated under fee-for-service plans but does not include bills for
those treated under Medicare managed care risk contracts (55). The sample was limited
to patients, aged 65 or older, discharged alive with a principal diagnosis of AMI utilizing
the International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9),
code 410.xx. Codes where the fifth digit was a “2” (410.x2) were excluded since this
represented an admission for a subsequent episode of care (10). With the exception of
five states (Alabama, Connecticut, Iowa, Wisconsin, and Minnesota), patients were
identified during an eight-month period using the Medicare National Claims History File.
All discharge dates were between February 1994 and July 1995. Because Alabama,
Connecticut, Iowa, and Wisconsin were the original four pilot states, hospitalizations
were sampled initially between June 1 and December 31, 1992 and then re-measured
between August 1 and November 30, 1995 (55). An ongoing study, the Minnesota
Clinical Comparison and Assessment Project (MCCAP) caused sampling in that state to
be delayed until April-November 1995 (51, 55).

Data Collection:
Medical record abstraction was performed by trained abstractors at two clinical
data abstraction centers established by the HCFA (now CMS). Predefined variables were
identified from the hospital record and entered directly into a computer database by
trained technicians (51). Random re-abstraction of 1,078 pairs of CCP cases was utilized
to ensure data reliability. Cases were re-abstracted between March 1, 1995 and
November 30, 1995 (7). Variable agreement, as shown in Table 2 below, varied from
91.6% to 98.3% (Kappa, 0.46-0.95) (7, 10, 51). Quality indicator reliability defined as
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the agreement rate between two abstractors assessing patient eligibility for a quality
indicator and subsequent receipt of the indicator varied from 93.5% to 98.6% (Kappa,
0.41-0.76) as depicted in Table 3 (7, 10).

Table 2: Reliability findings between AMI confirmation and CCP indicators
(Modified-Huff et al., Table 3 (7))

Quality Indicator

Observation
Rate (%)

Agreement
(%)

Opportunities to Improve Care (“Ideal” Candidates who did not receive
appropriate therapy)
Therapy Usage
Aspirin during hospitalization
6.9
96.1
Aspirin at discharge
5.8
96.2
Beta-blockers at discharge
3.5
97.5
ACE inhibitor at discharge
3.1
98.6
Thrombolysis administered
3.4
95.8
Reperfusion given
2.9
93.8
Smoking cessation counseling
at discharge
6.7
93.5

Kappa

0.69
0.41
0.64
0.76
0.41
0.53
0.53

Table 3: Reliability findings for CCP composite quality indicators representing
opportunities to improve care (Modified-Huff et al., Table 5 (7))

Indicator

Observation
Rate (%)

Agreement
(%)

Kappa

88.5

94.6

0.72

77.3
52.8
32.0
27.2
14.0
20.8

95.6
94.8
97.4
98.1
98.3
97.4

0.88
0.90
0.94
0.95
0.93
0.92

70.3

97.6

0.94

9.5

91.6

0.46

AMI Confirmation
Therapy Usage
Aspirin during hospitalization
Aspirin at discharge
Beta-blockers at discharge
ACE inhibitor at discharge
Thrombolysis administered
Reperfusion given
No calcium blockers at
discharge
Smoking cessation counseling
at discharge

AMI and Diabetes Definitions:
The criteria for a confirmed AMI was the following: a discharge diagnosis of an
AMI and chart documentation of either a creatine-kinase-muscle-brain isoenzyme (CK-
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MB) fraction greater than 0.05 or a lactate dehydrogenase (LDH) level more than 1.5
times normal with a LDH-1 level higher than a LDH-2 level or two of the following three
criteria: chest pain, a two-fold elevation of the CK level, or evidence of a new AMI on an
electrocardiogram. We did not use troponin levels since they were not widely in use
during 1994-1995, hence the necessary data was lacking. The diagnosis of diabetes
mellitus was based on chart documentation rather than diagnosis code. We did not use
admission serum glucose levels or HbA1c levels as a criterion for the diagnosis of
diabetes. We also did not distinguish type 1 diabetes from type 2 diabetes in our
subsequent analyses.

Quality of Care Indicators
Table 4 lists the quality of care indicator definitions, eligibility, and exclusion
criteria used in this study. Quality of care indicators were developed by a steering
committee convened by HCFA and the American Medical Association during the pilot
phase of the CCP (53). The quality of care indicators were based primarily on the
ACC/AHA treatment guidelines for AMI (53). Each indicator had specific criteria to
determine potential “eligible” candidates (those who could have received an
intervention). This population was subsequently subdivided into two groups: a) ideal
candidates—patients for whom treatment should be indicated; and b) less-than-ideal
candidates—patients for whom treatment was contraindicated, controversial, or for whom
data to determine the appropriateness of treatment was missing (53).
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Table 4: Quality of Care Indicators-Eligibility and Exclusion Criteria
Aspirin Prescribed During Hospitalization
Eligible:
Exclusions:

Criterion:

All patients with confirmed acute myocardial infarction (AMI)
Bleeding on admission, history of peptic ulcer disease or internal bleeding,
coagulopathy, chronic liver disease, allergy to aspirin, admission platelet count
<100x109/L, hemoglobin <10g/dL, hematocrit <30%, serum creatinine
>3mg/dL, treatment with warfarin on admission, metastatic cancer, or terminal
illness
Received aspirin on day 1 or 2

Aspirin Prescribed at Discharge
Eligible:
Exclusions:

Criterion:

All patients with confirmed acute myocardial infarction (AMI) discharged
alive and eligible for discharge therapies
Bleeding on admission or during hospitalization, history of peptic ulcer disease
or internal bleeding, acute upper gastrointestinal tract disorder during
hospitalization, bleeding, coagulopathy, chronic liver disease, allergy to
aspirin, admission platelet count <100x109/L, hemoglobin <10g/dL,
hematocrit <30%, serum creatinine >3mg/dL, treatment with warfarin on
discharge, metastatic cancer, or terminal illness
Aspirin prescription at discharge

Beta-Blocker Prescribed During Hospitalization
Eligible:
Exclusions:

Criterion:

All patients with confirmed acute myocardial infarction (AMI)
Heart rate <60/min, systolic blood pressure <100mm/Hg, second or thirddegree heart block, heart failure, left ventricular ejection fraction <50%,
bifasicular block, allergy or intolerance to beta-blockers, history of asthma,
chronic obstructive pulmonary disease, peripheral vascular disease, shock
Received beta-blockers on day 1 or 2

Beta-Blocker Prescribed at Discharge
Eligible:
Exclusions:

Criterion:

All patients with confirmed acute myocardial infarction (AMI) discharged
alive and eligible for discharge therapies
Heart rate <50/min at discharge (not currently on beta-blocker), systolic blood
pressure <100mm/Hg at discharge (not currently on beta-blocker), second or
third-degree heart block, heart failure and left ventricular ejection fraction
<50%, left ventricular ejection fraction <30% or described as severe
dysfunction, bifasicular block, allergy or intolerance to beta-blockers, history
of asthma, chronic obstructive pulmonary disease, peripheral vascular disease,
shock or hypotension during hospitalization
Beta-blocker prescription at discharge

Angiotensin-converting enzyme inhibitor (ACE-I) Prescribed at Discharge
Eligible:
Exclusions:
Criterion:

All patients with confirmed acute myocardial infarction (AMI) with left
ventricular ejection fraction <40% or described as severe or moderate
dysfunction discharged alive and eligible for discharge therapies
Aortic stenosis, allergy or intolerance to ACE-Is, systolic blood pressure
<100mmHg at discharge (not currently on ACE-I), serum creatinine >2mg/dL
ACE-I prescription at discharge

Receipt of Primary Percutaneous Transluminal Coronary Angioplasty (PTCA)
Eligible:

All patients with confirmed acute myocardial infarction (AMI), with ST
elevation or left bundle branch block on admission electrocardiogram, and
onset of symptoms within 12 hours
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Exclusions:

Stroke, coagulopathy, bleeding on admission, chronic liver disease, history of
internal bleeding or peptic ulcer disease, recent surgery (defined as within the
past 2 months), recent cardiopulmonary resuscitation, recent trauma, age >80
years, use of warfarin prior to arrival, evidence that thrombolysis was rejected
by patient or physician after initial consideration, cardiac catherization without
angioplasty within 12 hours after admission

Criterion:

Receipt of PTCA within 24 hours of admission

Timing of Thrombolytic Therapy
Eligible:
Exclusions:
Criterion:

Same as receipt of PTCA
Same as receipt of PTCA
Time from admission to initiation of thrombolytic therapy

Smoking Cessation Counseling
Eligible:
Exclusions:
Criterion:

All patients with confirmed acute myocardial infarction (AMI) discharged
alive with cigarette use within year of admission
None
Chart documentation of counseling on smoking cessation

Modified from Burwen et al., “National and State Trends in Quality of Care for Acute
Myocardial Infarction Between 1994-1995 and 1998-1999: The Medicare Health Care Quality
Exclusion/Inclusion
Improvement Program”Criteria
(Table 1) (10)

Our study sample included 234,769 Medicare patients aged 65 years or older
hospitalized with confirmed AMI and who were discharged alive. Only the first AMI
admission was included regardless of whether a patient was hospitalized for AMI more
than once during the sample period (51). We excluded all transferred patients due to the
inability to determine discharge medications. Those who were terminally ill (those with
less than 6-month survival as documented in the hospital records), those with “do not
resuscitate” (DNR) instructions, or those who had end-stage renal disease were also
excluded. After excluding those who were less than 65 years old, had terminal illness, or
who were transferred from another hospital, our final study sample was 203,658 patients.
For our quality of care analyses, we further restricted the cohort to ideal candidates only,
using the specific criteria developed for these indicators as detailed in Table 4.
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Demographic & Clinical Variables
Our demographic variables were age, sex, and race. Age was categorized as 65 to
74 years, 75 to 84 years, and 85 years and older. Race was dichotomized as white and
nonwhite. Clinical variables for each patient were collected from the medical record and
included past medical history, medications on admission/discharge, and in-hospital
characteristics and procedures. Comorbidities were obtained from chart documentation
and included the following: history of hypertension, stroke, congestive heart failure
(CHF), renal dysfunction (serum creatinine >2.5mg/dL or blood urea nitrogen >40
mg/dL), cancer, chronic obstructive pulmonary disease, history of myocardial infarction,
previous percutaneous transluminal coronary angioplasty (PTCA), previous coronary
artery bypass graft surgery (CABG), dementia, inability to ambulate, albumin level less
than 3g/dL, left ventricular ejection fraction (LVEF) less than 0.35, and anemia
(hematocrit <30). Smoking status was also obtained as documented in the chart.
Admission lab characteristics included respiratory rate greater than 25/min, prothrombin
time greater than 16 seconds, pulse greater than 100/min, and evidence of a left bundle
branch block on the admission electrocardiogram. In-hospital clinical characteristics and
procedures performed included recurrent chest pain, heart failure, stroke, creatine kinase
levels more than four times the normal level, PTCA, CABG, and measurement of LVEF.
Hospital length of stay was also abstracted. Documentation of medications during
admission included aspirin, beta blockers, and thrombolytic therapy. Discharge
medications included aspirin, beta blockers, ACE-Is, statins, and bronchodilators.
Diabetic medications were identified and abstracted from a file listing all medications
used by the cohort and included the following classes of medication: insulin, biguanides,
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sulfonylureas, and glucosidase inhibitors. Discharge disposition was coded as home,
long-term care, or died. Physician’s specialty was also abstracted based on information
listed in the Medicare Part A claims (51). Each physician’s identification number was
linked with the HCFA directory of physician-reported specialties (51).

Outcome Variable
Our outcome variable was all-cause mortality 3 and 10 years after hospital
discharge. Mortality was determined by linking patient data with the Medicare
Enrollment Database. The Enrollment Database contains information on all beneficiaries
ever enrolled in the Medicare program, including information on dates of death (69).
These dates are a compilation of data derived from discharge dates of billing records,
which indicate any discharge dispositions of death, and from the Master Beneficiary
Record, included as part of Social Security records (52).

Statistical Analysis:
Statistical analysis using 2-sided t-tests for differences in means, chi-squared tests
for comparison of categorical variables, and Cox proportional regression was used. The
data was primarily analyzed according to diabetic status. After testing and confirming
graphically that the proportionality assumption for Cox regression was met, a Cox
proportional hazards model was used to assess mortality differences. For all mortality
analyses time “0” was defined as patient admission to the hospital. We adjusted for
potential confounders by including the variables collected as described above:
demographics, clinical variables, physician specialty, hospital characteristics, and quality
of care indicators. A quality of care composite model was constructed that represented
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an opportunity-level composite score (7). Eight quality of care indicators were used to
calculate the opportunity and composite score for each patient: aspirin, acute reperfusion,
thrombolytics and beta-blocker on admission; aspirin, beta-blocker, ACE-I, and smoking
counseling at discharge. 2 A series of Cox proportional hazards models with adjustment
for clustering 3 on hospitals were constructed that sequentially adjusted for diabetic status,
demographics, clinical and medical history, and finally quality of care. We calculated
both unadjusted and adjusted hazard ratios with their respective 95% confidence intervals
(CIs). Kaplan-Meier survival curves were plotted and log-rank tests were calculated to
determine statistical differences between curves. We also created a diabetic risk-adjusted
model to determine the association between prescribed use of insulin, sulfonylureas,
biguanides, and statin therapy with 3 and 10-year survival. Similarly, we calculated both
unadjusted and adjusted hazard ratios with their respective 95% confidence intervals
(CIs). Statistical significance for p-values was set at α=0.05. All analyses were
performed using STATA 8.00 (STATA Corp, College Station, Tex).

IV. Statement of Student Contribution
This work was a collaboration between many individuals. Both Dr. JoAnne
Foody and Dr. Barbara Gulanski provided valuable feedback throughout the thesis
process. Dr. JoAnne Foody and Dr. Harlan Krumholz provided access to the CCP
database. All statistical analyses were performed by Yun Wang, Ph.D. (Center for
Outcomes Research and Evaluation, Yale University). I, along with Drs. Foody and
2

For example, if a patient was eligible for both aspirin on admission and beta-blocker and ACE-I at
discharge, then this patient had three opportunities (denominator). However, if this patient only received
two of these therapies (numerator) the overall composite score for this patient would be 0.66.
3
The statistical command “cluster” specifies observations as independent across groups (clusters) but not
necessarily within groups [70]. Stata Corporation. Statistics Data Management Graphics Reference G-0.
College Station: Stata Corporation; 1997.
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Gulanski, developed the aims, hypotheses, and collectively analyzed the conclusions of
this study. All literature searches were performed by this author.

V. Results
Characteristics of the Sample
Diabetics comprised 32% (64,648) of the sample. The demographic and clinical
characteristics of diabetic and non-diabetic patients are shown in Table 5 below.

Table 5: Baseline Patient Characteristics By Diabetic Status
No. of Patients with
Characteristic by Diabetic
Status (%)
Diabetic
Non-Diabetic
(N=64,648)
(N=139,010)

Characteristics
Demographic information
Age, mean (SD)
Age 65 – 74
Age 75 – 84
Female
White

75.3 (6.8)
36,283 (49.9)
25,606 (39.6)
37,226 (52.9)
55,764 (86.3)

76.5 (7.5)
62,110 (44.7)
54,069 (38.9)
64,827 (46.6)
127,958 (92.1)

<0.001
<0.001
0.603
<0.001
<0.001

Medical History and Comorbid Conditions
Previous MI
Previous PTCA
Previous CABG
History of CHF
History of CVA
History of Chest Pain
Hypertension
Peripheral Vascular Disease
Current Smoker
Dementia
Unable to Ambulate

22,601 (35.0)
5,262 (8.1)
9,195 (14.2)
18,705 (28.9)
10,893 (16.9)
18,711 (28.9)
46,031 (64.8)
9,427 (13.3)
7,000 (10.8)
3,412 (5.3)
16,266 (25.2)

39,278 (28.3)
9,563 (6.9)
16,175 (11.6)
23,883 (17.2)
16,244 (11.7)
38,573 (27.8)
80,149 (57.7)
11,249 (8.5)
22,691 (16.3)
8,098 (5.8)
26,443 (19.0)

<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001

Admission Characteristics
Creatinine > 2.5 mg/dL or BUN > 40 mg/dL
Creatinine, mean (SD)
BUN, mean (SD)
Albumin < 3 g/dL
Hematocrit < 30

8,882 (13.7)
1.5 (1.1)
25.5 (14.3)
3,551 (5.5)
3,729 (5.8)

10,472 (7.5)
1.3 (0.9)
21.8 (11.7)
5,957 (4.3)
6,244 (4.5)

<0.001
<0.001
<0.001
<0.001
<0.001

p
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Table 5: Baseline Patient Characteristics By Diabetic Status

Characteristics
Prothrombin Time > 16 sec
Respiratory Rate > 25/min
Pulse > 100/min
CVA on Admission
Left Bundle Branch Block
LVEF < 0.35

No. of Patients with
Characteristic by Diabetic
Status (%)
Diabetic
Non-Diabetic
(N=64,648)
(N=139,010)
3,871 (6.0)
7,350 (5.3)
13,795 (21.3)
22,126 (15.9)
3,794 (5.9)
7,315 (5.3)
720 (1.1)
1,459 (1.1)
4,635 (7.2)
7,559 (5.4)
11,819 (18.3)
19,855 (14.3)

p
<0.001
<0.001
<0.001
0.346
<0.001
<0.001

Medications During Admission
Aspirin
Beta Blockers
Thrombolytics

28,884 (83.0)
25,147 (50.4)
2,270 (49.8)

66,235 (85.6)
58,781 (56.3)
7,280 (63.2)

<0.001
<0.001
<0.001

Hospital Procedures and Course
Cardiac Catheterization
PTCA
CABG
LVEF measured
Creatine Kinase > 4 times normal level
Mean (SD) Length of Stay, if LOS ≤30 days

23,951 (33.7)
7,689 (11.9)
5,920 (9.2)
41,602 (64.4)
18,376 (28.4)
7.38 (5.0)

52,173 (37.5)
21,860 (15.7)
12,595 (9.1)
89,860 (64.6)
44,911 (32.3)
6.82 (4.7)

<0.001
<0.001
0.479
0.201
<0.001
<0.001

Discharge disposition
Home
Discharged to long term care
Died

39,466 (61.1)
5,399 (8.4)
7,912 (12.2)

87,298 (62.8)
10,803 (7.8)
14,108 (10.2)

0.480
<0.001
<0.001

* Table values are mean ± SD for continuous variables and No. (%) for categorical variables.
Percentages may not sum to 100% due to rounding.
MI=Myocardial Infarction; PTCA=Percutaneous Transluminal Coronary Angioplasty
CABG=Coronary Artery Bypass Graft; CHF=Congestive Heart Failure
CVA=Cerebral Vascular Accident; BUN=Blood Urea Nitrogen; Hct=Hematocrit
LVEF=Left Ventricular Ejection Fraction

Compared to non-diabetics, diabetics were younger (75 vs. 76, p<0.001). A
greater proportion of diabetics were female (53%, p<0.001) and nonwhite (86.3% vs.
92.1%, p<0.001). With regards to medical history and comorbidities, diabetics were
more likely to have had a previous MI (35% vs. 28.3%), a history of CHF (28.9% vs.
17.2%) or stroke (16.9% vs. 11.7%), or had previous revascularization procedures, either
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PTCA (8.1% vs. 6.9%) or CABG (14.2% vs. 11.6%) (all, p<0.001). On admission,
diabetics were almost twice as likely to have renal dysfunction as measured by a serum
creatinine greater than 2.5mg/dL or BUN greater than 40mg/dL level (13.7% vs. 7.5%,
p<0.001). Diabetics were more likely to present with an admission albumin level less
than 3g/dL (5.5% vs. 4.3%), hematocrit less than 30 (5.8% vs. 4.5%), and a prothrombin
time greater than 16 seconds (6.0% vs. 5.3%) (all, p<0.001). Diabetics were also more
likely to have on admission a left bundle branch block (7.2% vs. 5.4%, p<0.001) and a
left ventricular ejection fraction less than 0.35 (18.3% vs. 14.3%, p<0.001), indicating
poorer cardiac status. However, diabetics were less likely to have creatine kinase levels
greater than 4 times the normal level (28.4% vs. 32.3%, p<0.001).
In terms of hospital procedure and course, diabetics were less likely to undergo
PTCA (11.9% vs. 15.7%, p<0.001). Mean length of stay was slightly longer for diabetic
patients (7.38 days ± 5.0 vs. 6.82 days ± 4.7, p<0.001). Diabetics were as likely to be
discharged home as non-diabetics (61.1% vs. 62.8%, p=0.480). However, those
discharged to a long-term care facility were more likely to be diabetic (8.4% vs. 7.8%,
p<0.001). Patients who died during initial hospitalization were also more likely to be
diabetic (12.2% vs. 10.2%, p<0.001).

Medications During Admission and at Discharge
On admission, diabetics were less likely to be prescribed aspirin (83.0% vs.
85.6%, p<0.001), beta blockers (50.3% vs. 56.3%, p<0.001), or thrombolytic therapy
(49.8% vs. 63.2%, p<0.001). At discharge, 63% of diabetics were on some form of
diabetic medications (26.2% were on insulin therapy and 36.5% were prescribed oral
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hypoglycemics, including sulfonylureas/biguanides 4 : data not shown). Although not the
standard of care during 1994-1995, nonetheless, statin therapy was prescribed equally to
both diabetics and non-diabetics (4.5% vs. 4.6%, p=0.582) 5 . As depicted in Figure 7,
among ideal candidates at discharge, diabetics were less likely to be prescribed aspirin
(63.8% vs. 69.0%, p<0.001) and beta-blocker therapy (36.3% vs. 42.0%, p<0.001),
whereas they were more likely to be prescribed ACE-Is (60.0% vs. 54.8%, p<0.001).
70%

P<0.001

60%

P<0.001
69%
60%

64%
50%

55%

P<0.001
40%
42%
30%

DM
Non-DM

36%

20%

10%

0%
BetaBlocker

Aspirin

ACE-I

Figure 7: Percent of Diabetic vs. Non-Diabetic Patients Receiving Evidence-Based
Medications at Discharge (Among Ideal Candidates)
10-Year Mortality
Our primary analysis revealed a difference in mortality rates between diabetics
and non-diabetics throughout the entire 10-year period (Figure 8). In-hospital deaths (i.e.
at time of initial hospitalization for AMI) were 12%. Overall mortality for the study
sample at 10 years was 69.4%. Compared to non-diabetics, the overall unadjusted 10year mortality for diabetics was higher (77.2% vs. 65.4%). We constructed multivariate
4

The most prescribed sulfonylurea was glipizide. The only prescribed biguanide was metformin. Because
of the relatively small numbers of patients on biguanide therapy, we combined sulfonylureas and
biguanides in subsequent analyses. Only 1 patient was on glucosidase inhibitors and thus this class of
medication was not included in any analyses.
5
The most prescribed statin was lovastatin.
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models using Cox proportional regression to estimate the overall 10-year mortality risk
for diabetics and to adjust for confounders (Table 6). In the unadjusted model we
constructed, diabetics had higher 10-year mortality rates as compared to non-diabetics
(HR=1.38, 95% CI: 1.37-1.40). After addition of demographic and clinical
characteristics to the unadjusted models, the hazard ratio was 1.30 (95% CI: 1.28-1.31).
After adjusting for demographics, past medical history, procedures during hospitalization,
medications on admission/discharge, and quality of care, the hazard ratio was 1.29 (95%
CI, 1.27-1.31).

Non-Diabetic

Diabetic

Figure 8: Differences in Survival Between Diabetics and Non-Diabetics Post-MI
(10 Year Data-Unadjusted)

Table 6: 10-Year Mortality
Unadjusted

HR

95% CI

Non-diabetics
Diabetics

1.00
1.38

-(1.37-1.40)

1.00
1.30

-(1.28-1.31)

Adjusted for Demographics & Clinical Variables
Non-diabetics
Diabetics

Adjusted for Demographics, Clinical Variables, & Quality of Care Indicators
Non-diabetics
Diabetics

1.00
1.29

-(1.27-1.31)
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As part of our secondary analyses, we also examined mortality differences
between patients who were prescribed statin therapy at discharge and those who were not
prescribed statins. The overall 10-year mortality for the statin group was lower compared
to those not prescribed statin therapy (54.7% vs. 70.1%). Among the group not
prescribed statin therapy, diabetics had a higher mortality rate compared to non-diabetics
(77.7% vs. 66.3%). Interestingly as noted above, although there were no statistically
significant differences in prescription rates of statin therapy for diabetics vs. nondiabetics (4.5% vs. 4.6%, p<0.001), we found that the overall 10-year mortality rates for
diabetics on statin therapy was higher as compared to non-diabetics on statins (67.7% vs.
48.1%, p<0.001; Figure 9).

Non-Diabetic on statin therapy

Diabetic on statin therapy

Figure 9: Differences in Survival Between Diabetics on Statin Therapy and
Non-Diabetics on Statin Therapy Post-MI (10 Year Data-Unadjusted)
We further restricted our analysis to diabetic patients only in order to analyze the
effect of statin therapy on this cohort. Among diabetic patients those on statin therapy
had lower 10-year mortality than those not prescribed statin therapy (67.7% vs. 77.7%,
Figure 10).
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Diabetic on Statin Therapy

Diabetic not on Statin Therapy

Figure 10: Differences in Survival Between Diabetics on Statin Therapy and Diabetics
not on Statin Therapy Post-MI (10 Year Data-Unadjusted)
We conducted further analyses with respect to diabetic related medications.
Similarly, diabetic patients on oral medications (sulfonylureas and biguanides) had better
10-year mortality outcomes compared to diabetic patients not on oral hypoglycemics
(Figure 11). However when restricting our analysis to insulin therapy, our Kaplan-Meier
survival curves crossed between three and four years post-MI (Figure 12) suggesting nonproportionality. In our subsequent multivariate analysis as depicted below, mortality
outcomes between diabetics and non-diabetics were analyzed from admission to three
years and from four years to ten years post-MI. Table 7 depicts unadjusted mortality
rates for years 1-5 and at 10 years for diabetic patients on insulin and those not on insulin
at discharge confirming our Kaplan-Meier findings.
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Diabetic on Sulfyonlureas/Biguanides

Diabetic not on Sulfyonlureas/Biguanides

Figure 11: Differences in Survival Between Diabetics on Sulfonylurea/Biguanide
Therapy and Diabetics not on Sulfonylurea/Biguanide Therapy Post-MI (10 Year
Data-Unadjusted)

Diabetic on Insulin
Diabetic not on Insulin

Diabetic on Insulin

Figure 12: Differences in Survival Between Diabetics on Insulin Therapy and
Diabetics not on Insulin Therapy Post-MI (10 Year Data-Unadjusted)
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Table 7: Unadjusted Mortality for Diabetic Patients Receiving Insulin
therapy Post-MI: Years 1-5 & 10
Year Post-MI
1
2
3
4
5
10

Mortality Rate
On Insulin Therapy
Not On Insulin Therapy
27%
39%
48%
57%
64%
80%

35%
44%
50%
56%
61%
77%

P
<0.001
<0.001
0.008
0.027
<0.001
<0.001

Medication Use and Mortality Among Diabetics: Multivariate Analysis
We also constructed a diabetic risk-adjusted model, limiting our analysis to
diabetic patients. In particular, we were interested in analyzing the relationship between
medication use (insulin, sulfonylureas/biguanides, and statins) and long-term mortality
(Table 8). We analyzed the data in two time periods: 1) time from hospital admission to
3 years (includes in-hospital related deaths); and 2) time from year 4-year 10 (excludes
in-hospital related deaths). Our choice of these time periods are fully described in the
introduction. For this analysis, we adjusted for demographics, clinical characteristics,
medications on admission/discharge, and quality of care indicators.
As depicted in Table 8, statin use at both time periods was associated with
decreased mortality among diabetics. During the first three years, in the unadjusted
model, the hazard ratio for use of statin therapy was 0.58 (95% CI: 0.54-0.62). With full
adjustment this protective effect was reduced to 0.73 (95% CI: 0.69-0.78). During the
second time period, the unadjusted hazard ratio was 0.90 (95% CI: 0.84-0.95). However,
once we adjusted for demographics, clinical characteristics, and quality of care, statin use
was no longer associated with a decrease in mortality (HR=0.95, 95% CI: 0.90-1.05).
Similarly in our unadjusted models, both insulin use and sulfonylureas/biguanides were
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associated with decreased mortality among diabetics during the first three years post-MI
(HR for insulin=0.75, 95% CI: 0.73-0.77; HR for sulfonylureas/biguanides=0.55, 95%
CI: 0.54-0.57). This association remained even after full adjustment for demographics,
clinical characteristics, and quality of care (HR for insulin=0.73, 95% CI: 0.71-0.75; HR
for sulfonylureas/biguanides=0.63, 95% CI: 0.62-0.65). However, analysis of our second
time period revealed that both insulin and sulfonylureas/biguanides were associated with
increased mortality among diabetics during years 4 through 10. In our fully adjusted
model, the hazard rate for sulfonylureas/biguanides use was 1.11 (95% CI: 1.08-1.15)
while the hazard rate for insulin use was 1.30 (95% CI: 1.25-1.35). Of patients on
sulfonylureas/biguanides, 7.9% were also on insulin therapy and thus we observed an
interaction between insulin and sulfonylureas/biguanides (data not shown).

Table 8: Sequential Multivariate Cox Proportional Hazards
Models Evaluating Medication Use (Insulin; Sulfonylureas &
Biguanides; Statins) and Mortality in Diabetics During 2 Time
Periods: Years 0-3 & Years 4-10
Model

Years 0-3*
Hazard Ratio 95% CI

Years 4-10
Hazard Ratio 95% CI

1. Unadjusted
Insulin
0.75
0.73-0.77
1.31
1.26-1.35
Sulf/Big
0.55
0.54-0.57
1.05
1.02-1.09
Statins
0.58
0.54-0.62
0.90
0.84-0.95
2. Adjusted for Demographics
Insulin
0.78
0.76-0.80
1.39
1.34-1.44
Sulf/Big
0.55
0.54-0.57
1.06
1.02-1.09
Statins
0.66
0.62-0.70
0.98
0.92-1.05
3. Adjusted for Demographics, Clinical Variables, & Quality of Care
Insulin
0.73
0.71-0.75
1.30
1.25-1.35
Sulf/Big
0.63
0.62-0.65
1.11
1.08-1.15
Statins
0.73
0.69-0.78
0.95
0.90-1.02
*Includes in-hospital deaths=12%
Sulf/Big=Sulfonylureas/Biguanides
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VI. Discussion
The principal finding of our study is that 10-year mortality for diabetics is higher
than for non-diabetics. Our study is unique because we showed that after full adjustment
for demographics, clinical variables, and quality of care indicators, diabetics still had a
29% increase in mortality compared to non-diabetics. Our results are consistent with
previous studies which demonstrate that diabetics have increased mortality after
myocardial infarction (20, 22, 24, 47, 71-73). Our results extend these findings because
we had long-term follow-up data and we were also able to adjust for differences in
quality of care among the two groups. Our findings suggest that neither patient
characteristics nor quality of care fully account for the poor outcomes among diabetics,
suggesting that metabolic risk factors associated with diabetes ultimately require
therapies beyond those currently recommended for post-MI patients.
The aims of this study were: 1) to measure and compare 10-year mortality rates
for diabetic and non-diabetic patients hospitalized with AMI; 2) to measure compliance
rates with established guidelines in place during 1994-1995 regarding cardiac
medications as a secondary prevention strategy among diabetic and non-diabetic patients
hospitalized with AMI; and 3) to investigate the role of statin and diabetic therapies
(insulin/oral hypoglycemics) in decreasing 3 and 10-year mortality rates for diabetics
hospitalized with AMI. With regards to our aim of measuring compliance rates with
established guidelines regarding cardiac medications as a secondary prevention strategy
among diabetic and non-diabetic patients hospitalized with AMI, we found that aspirin
was not prescribed to 35.5% of diabetics who were ideal candidates for the therapy.
Among this group of ideal candidates, beta-blockers were also not prescribed to 63.4% of
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diabetics eligible for the therapy. Equally surprising was that overall use of aspirin and
beta-blocker therapy at discharge was also low for non-diabetics eligible to receive them.
Less than 70% of non-diabetics were prescribed aspirin at discharge and less than 50% of
non-diabetics eligible for beta-blockers were prescribed the medication at discharge. Our
results are consistent with other studies that have demonstrated that diabetics are less
likely to receive evidence-based care post-MI (21, 23, 24, 47, 48, 56). The strength of
our study was not only in validating the results of other investigators but we believe our
study was able to extend these findings because we limited our analysis to ideal
candidates. We believe that our study is valuable for it is in line with the original primary
aims of the CCP initiative: to describe quality of care practices among ideal candidates
hospitalized with AMI. Our results suggest that there is opportunity for improvement in
management of diabetics post-MI since our data confirms that diabetics receive
suboptimal medical care.
Underutilization of both aspirin and beta-blockers is surprising since both
therapies are a proven and effective secondary prevention strategy for patients post-MI.
Additionally, at the start of our study in 1994, ACC/AHA guidelines recommended use
of both therapies as secondary prevention strategies for patients post-MI. A metaanalysis of more than 18,000 patients enrolled in randomized controlled trials through
March 1990 demonstrated that antiplatelet therapy reduced long-term mortality in both
diabetic and non-diabetic patients (74). As noted in the introduction, a possible
explanation as to why aspirin and beta-blockers may have been underutilized in diabetic
patients is due to the controversies surrounding both therapies at the initiation of our
study. The 1990 ACC/AHA guidelines suggested caution when prescribing beta-blocker
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therapy for insulin-dependent diabetics most likely due to the theory that hypoglycemic
symptoms would be masked as a result of the blunting of reflex tachycardia by betablocker therapy. However, this would not explain why non-diabetics were also not
receiving this important therapy. With regards to aspirin therapy, although the results of
the ETDRS in 1992 showed that aspirin did not increase the risk of ocular hemorrhage,
ADA practice guidelines did not recommend aspirin for diabetics until 1997. This may
have been due to an additional concern regarding a possible interaction between aspirin
and ACE-Is in terms of renal function (75, 76). One study showed that among patients
with severe CHF, aspirin therapy attenuated the vasodilator effects of the ACE-I enalapril
(77). A subgroup analysis of the Cooperative New Scandinavian Enalapril Survival
Study II (CONSENSUS II) demonstrated a negative interaction between enalapril and
aspirin and that this interaction was a predictor of mortality (p=0.047). Interestingly, our
study showed that among ideal candidates diabetics were more likely to be prescribed
ACE-Is as compared to non-diabetics (61% vs. 55% p<0.001). This may suggest that
physicians were indeed concerned about a possible adverse interaction between ACE-Is
and aspirin and thus chose one therapy over the other. Both Norhammar et al. and
Vaccarino et al. in their respective studies also have demonstrated that compared to nondiabetics, diabetics are more likely to be prescribed ACE-Is as opposed to aspirin or betablockers (21, 47). However, none of the authors proposed an explanation for this finding.
Additionally, unlike our study, their analyses were not restricted to ideal candidates and
thus their cohort may have been comprised of diabetics with nephropathy requiring the
use of ACE-Is.
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While it is important to acknowledge the controversies that existed during the
time of our study which may have contributed to the decreased prescription of therapies
among diabetics, our findings that among ideal candidates even non-diabetics were
receiving suboptimal care suggest that physicians’ adherence to guidelines is less than
ideal. As noted previously, evidence exists from several studies that there is
underutilization of evidence-based therapies among the elderly in general (10, 46, 49-56,
78-81). Consequently, this was the impetus behind the creation of the CCP. Although
great strides have been undertaken to improve quality of care for the elderly and diabetics
over the past decade, recent studies show that there are still significant disparities in
healthcare especially for diabetics (82, 83). Grant et al. in a retrospective cohort study of
1,765 diabetic patients conducted from 2000-2002 in 30 US academic medical centers
demonstrated that physicians did not make appropriate medication adjustments to meet
practice guideline goals such as HbA1c levels less than 7%, blood pressure less than
130/80 mmHg, or lipid goals less than 100 mg/dL (84) suggesting that greater
improvements are needed in this area.
In order to acknowledge paradigm shifts in medical care that may have
unknowingly influenced results from our study, we analyzed our data in two time periods
and further restricted our analysis to diabetics only. Unfortunately, because this is a
retrospective study, it is difficult to determine with certainty to what extent if any our
data is subject to a period effect. We were concerned given the controversies that existed
with regards to medical therapy that there were systematic differences between groups
that would have influenced our data. For example, because of the national scope of our
data, academic centers, where many of these landmark studies originated, may have
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treated diabetics more aggressively even before practice guidelines officially changed as
opposed to community hospitals. We tried to limit this by controlling for hospital
characteristics and adjusting for clustering among hospitals but there may be additional
unknown confounders for which we did not adjust. We did not apply further regression
techniques to explore this issue and is a limitation of our study.
Surprisingly, the analysis of our data in two time periods revealed an interesting
relationship between insulin therapy and mortality within the diabetic cohort. Within the
first three years, in our fully adjusted model, insulin therapy was associated with
decreased mortality (HR=0.73, 95% CI: 0.71-0.75) whereas in the remaining seven years,
it was associated with increased mortality (HR=1.30, 95% CI: 1.25-1.35). The same was
true for sulfonylurea/biguanide therapy (HR years 0-3=0.63, 95% CI: 0.62-0.65; HR
years 4-10=1.11, 95% CI: 0.71-0.75). Berger et al. also found an increased risk of
mortality with insulin use while a study by Chyun et al. did not find this association (22,
24). It is important to note that both authors used data from the CCP but only analyzed
short-term mortality. The study by Berger et al. was national in scope whereas the study
by Chyun et al. was limited to Connecticut. Although our data revealed an increase in
mortality after the third year while Berger et al. found this association at one year, we
agree with the conclusions of Berger et al. and believe this most likely represents
confounding and that this association represents increasing disease burden among
diabetics as time progresses. In other words, insulin may just be a marker of disease
progression. We cannot draw any firm conclusions because we did not have information
on medication dosages so we cannot fully correlate medication with outcomes. We
cannot determine if those who reaped a benefit in the first three years were on high or
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low dosages of insulin, whether they had just been started on therapy during initial
hospitalization for AMI, or what their admission glucose levels/HbA1c were. It is known
that stress hyperglycemia at the time of initial MI can increase the risk of death. A recent
meta-analysis described that non-diabetics who had glucose concentrations between 6.18.0 mmol/L had a 3.9 increased risk of mortality (95% CI: 2.9-5.4) as compared to nondiabetics with lower glucose concentrations. Higher range of glucose concentrations
(8.0-10.0 mmol/L) increased the risk of CHF or cardiogenic shock. Among diabetic
patients those with glucose concentrations between 10-11.0 mmol/L had a 1.7 increased
risk of mortality (95% CI: 1.2-2.4) (85).
An alternative, but admittedly less likely explanation for our finding is that this
may represent “metabolic memory” similar to the recent findings of the Epidemiology of
Diabetes Intervention and Complications (EDIC) study, an 11-year follow-up of DCCT
participants. The EDIC study showed that CVD events were reduced years after
intensive insulin therapy among type 1 diabetics had ended in the original randomized
controlled trial (86). However, unlike our study this was a randomized controlled trial in
type 1 diabetics who had undergone years of intensive insulin therapy. It is highly
unlikely that patients received an intensive insulin regimen during hospitalization and if
they did, as mentioned previously, we do not have information regarding medication
dosages to determine the effect. Additionally, we do not have information regarding type
of diabetes or duration of disease. Thus, without information regarding type of diabetes,
duration of disease, medication dosages, and glycemic-related admission characteristics,
we cannot analyze this finding further or make any firm conclusions. How intensive
insulin therapy affects CVD and long-term outcomes will most likely be answered by
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several ongoing randomized controlled trials such as the Action to Control
Cardiovascular Risk in Diabetes (ACCORD) study, results for which are expected in
2009.
Similarly our findings for sulfonylureas are difficult to interpret. We were
surprised to find that while our unadjusted Kaplan-Meier curve did not indicate a crossover in mortality between years 3 and 4, our Cox regression models did. As indicated
previously, a proportion of patients on sulfonylureas were also on insulin therapy. Our
findings most likely suggest an interaction between these therapies, however we were not
able to evaluate this further and is a limitation of our study. Additionally, there has been
conflicting information regarding the effect of sulfonylureas and CVD mortality.
Because sulfonylureas close potassium channels, it has been hypothesized that closure of
these channels in cardiac cells impairs ischemic preconditioning, which normally allows
cardiac cells to survive during periods of ischemia (87). Another theory is that
sulfonylurea toxicity is pro-arrhythmic (87). The University Group Diabetes Project
(UGDP) study demonstrated that those treated with the sulfonylurea agent, tolbutamide,
had higher cardiovascular-related deaths than those on placebo whereas results from the
UKPDS showed that sulfonylurea therapy with glyburide did not increase risk of death
(88, 89). A recent meta-analysis demonstrated that a dose-response relationship exists
among first generation sulfonylureas and glyburide therapy and mortality among type 2
diabetics (87). It should be noted that in our study the most prescribed sulfonylurea was
glipizide which was not specifically studied in this meta-analysis but both glyburide and
tolbutamide were also used by patients in our cohort. Again, because we did not abstract
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information on medication dosages, we cannot adequately evaluate the relationship
between sulfonylureas and mortality.
In contrast, we demonstrated that statin therapy was mostly associated with
decreased mortality over the 10-year time period (HR years 0-3 fully adjusted
model=0.73, 95% CI: 0.69-0.78; HR years 4-10 fully adjusted model=0.95, 95% CI:
0.90-1.02). Statin therapy is now the mainstay of cardiac therapy and thus it is not
surprising that as numerous studies such as the Scandinavian Simvastatin Survival Study
Group (4S), the Cholesterol and Recurrent Events (CARE) trial, and the Long-Term
Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group have
demonstrated, statin therapy decreases mortality even among diabetics (90-93).

Strengths and Limitations
Our study was subject to several limitations. First, because this is a retrospective
study it is subject to limitations inherent to such a design. The data used in this study is
only reflective of what was documented in patients’ charts. Certain therapies may not
have been recorded. Errors in medical abstraction could have also occurred, especially in
the identification of ideal candidates, leading to misclassification. This misclassification
is most likely non-differential and would bias our results toward the null. Medical record
abstraction is difficult because charts may sometimes be illegible, poorly organized, and
because charts are written as narratives rather than standardized forms, the ability to
abstract the necessary data may be challenging (10, 55). Although validation studies of
the CCP have documented high reliability of the data abstracted (7), the data is not
perfect. Lastly, because we excluded transferred patients we may have introduced a
selection bias.
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As compared to randomized controlled trials, observational studies are often
subject to uncontrolled confounding. Because we only abstracted clinical data regarding
cardiac and diabetic medications we cannot account for use of other medications either
physician prescribed or over-the-counter medications (i.e. vitamins), that may have
affected our analysis. For example, we do not have information on the percentage of
women in the cohort who may have been taking hormone replacement therapy (HRT)
which at the time of our study was thought to decrease the risk of coronary events (94).
This is an important confounder because after the initiation of our study, results from the
Women’s Health Initiative in 2003 showed that HRT increases cardiovascular-related
mortality (95). Other important confounders to consider are socioeconomic status,
education, and lifestyle characteristics such as exercise, including cardiac rehabilitation
post-MI, and diet.
Most importantly, the CCP was not originally designed to assess diabetic
outcomes. As mentioned previously, we did not distinguish between the different types
of diabetes in our sample. Also, we did not have information regarding duration of
disease or several important admission characteristics such as body mass index, glycemic
variables (i.e. HbA1c levels or fasting plasma glucose levels), lipid levels, or medication
dosages. Because diabetic status was not confirmed via measurement of HbA1c levels or
fasting plasma glucose levels, we may have underestimated the prevalence of diabetes,
potentially resulting in disease misclassification. Again, this most likely represents nondifferential disease misclassification biasing our results towards the null. It should be
noted that statin therapy was not part of the standard of care during this time period and
no quality of care indicators were developed for this therapy. We were unable to
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correlate cholesterol levels on admission with statin therapy and we could not reliably
determine what the independent effect of statin use in this cohort had on long-term
mortality. However, although it was not the standard of care during this time period,
statin therapy was prescribed equally to both diabetics and non-diabetics (4.5% vs. 4.6%,
p=0.582). Furthermore, among those treated with evidence-based therapies, we do not
know whether patients were treated to target levels so we cannot reliably determine the
effect this had on mortality. With regards to our primary outcome, mortality, we did not
analyze cardiovascular-related mortality but rather all-cause mortality. Lastly, practice
guidelines for the care of patients with AMI along with diabetic management have
changed considerably. Thus, caution should be employed when trying to generalize these
findings to a contemporary cohort.
Although we acknowledge these limitations, we believe our study has several
strengths. The CCP is a well-known, large cohort that has been validated and provides a
comprehensive picture of the quality of care of elderly patients hospitalized with AMI.
Numerous published studies have used data from the CCP to describe treatment practices
for patients with AMI and describe changes over time with regards to the quality of care
patients hospitalized with AMI have received (10, 22, 24, 47, 51, 52, 55, 57). However,
data regarding diabetic patients in this cohort have been minimal especially with regards
to long-term follow-up. This is the first time that 10-year mortality data from the CCP
cohort looking at diabetic mortality has been presented. 6 We limited our mortality
analysis to patients who were ideal candidates for these therapies. Therefore, we were
able to examine the impact quality of care had on long-term mortality outcomes.

6

We presented an abstract of some of our initial findings at both the ADA Scientific Sessions (San Diego,
California, June 2005) and the AHA Scientific Sessions (Dallas, Texas, November 2005).
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Because the CCP utilizes cases from the Medicare databases, we were able to decrease
selection bias that may result from randomized trials. Use of Medicare data also
eliminates the ability to pay for care as a confounder in our study. While we recognize
practice guidelines have changed considerably, it has also been noted that practice
guidelines are slow to disseminate and thus the patterns we observed in our study with
regards to treatment and procedure use may in fact be reflective of care patients received
several years post 1994-1995 (81, 96, 97).

Conclusion
The impetus behind this thesis was to determine reasons behind the observed
increased mortality diabetics face post-MI and to determine how quality of care impacts
long-term outcomes for this group. As discussed, several authors have attempted to
characterize whether this increased short-term mortality is due to biological differences
or whether this increased mortality is due to health disparities-namely a difference in the
quality of care diabetics receive post-MI. Additionally, few studies have specifically
examined long-term mortality for diabetics post-MI. Our findings that both non-diabetics
and diabetics were less likely to receive evidence-based therapies post-MI suggest that
we need to encourage physicians to adopt and better implement evidence-based
guidelines especially for those historically most vulnerable to disparities in healthcare:
the elderly and diabetics. As the number of diabetics increase worldwide and as the
population ages, elderly diabetics will be the group most in need of new and effective
strategies in order to successfully combat their diseases and decrease their mortality. As
recently demonstrated by Eagle et al., the implementation of guideline-based AMI
standard care is associated with improved 30-day and 1-year mortality within a Medicare
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cohort post-MI (98). By extension, we believe that implementing guideline-based AMI
standard care can likely improve long-term outcomes as well. However, our findings
also suggest that even after accounting for quality of care, diabetics still have a
substantial increase in long-term mortality. While our study is one of the first to
highlight long-term mortality outcomes for elderly diabetics, more research is clearly
needed in this field. For example, future studies examining sex-based differences with
regards to long-term mortality for elderly diabetics will be valuable. Studies also
examining cardiovascular-related mortality will be extremely informative. We believe
that in order for this research to be successful, it will require a collaboration between
basic scientists, clinicians, and epidemiologists to identify and address both the
underlying metabolic factors and disparities in quality of care that clearly place elderly
diabetics at greatest risk of mortality post-MI.
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VII. Appendix

A1. Estimated Prevalence of Diabetes Worldwide: Year 2000 and 2030. Source:
World Health Organization (4)
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A2. Estimated Prevalence of
Diabetes by Age Group
(Developed vs. Developing
Countries): Year 2000 and
2030. Source: World Health
Organization (2)

A3. Incidence of Myocardial
Infarction in Diabetics and
Non-Diabetics with and
without prior MI. Source:
“Diabetes and Cardiovascular
Disease: Time to Act”
International Diabetes
Federation (6)
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